Skip to main content
Clinical Trials/NCT05417503
NCT05417503
Completed
Not Applicable

Acute Effects of NIV on Peripheral Muscle Function and Aerobic Performance in Patients With Chronic Obstructive Pulmonary Disease: a Piloty Study

Universidade Federal do Rio Grande do Norte1 site in 1 country14 target enrollmentDecember 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Obstructive Pulmonary Disease
Sponsor
Universidade Federal do Rio Grande do Norte
Enrollment
14
Locations
1
Primary Endpoint
Lung function
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Background: Non-invasive ventilation (NIV) reduces respiratory load and demands on peripheral muscles. Methods: This study aims to evaluate the acute effects of bi-level NIV on peripheral muscle function during isokinetic exercise and aerobic performance in chronic obstructive pulmonary disease (COPD) patients. This is a pilot crossover study performed with a non-probabilistic sample of 14 moderate to very severe COPD patients. Procedures carried out in two days. Dyspnea, quality of life, lung function, respiratory muscle strength, functional capacity (6-minute walk test - 6MWT), and isokinetic assessment of the quadriceps were assessed. Blood samples (lactate, lactate dehydrogenase, and creatine kinase concentration) were also collected. Right after, NIV was performed for 30 minutes (bi-level or placebo, according to randomization) followed by new blood sample collection, 6MWT, and isokinetic dynamometer tests. Before and after evaluations, the subjective perception of dyspnea and fatigue in the lower limbs was quantified. After a wash-out period of seven days, participants returned, and all assessments were performed again.

Registry
clinicaltrials.gov
Start Date
December 1, 2017
End Date
February 28, 2018
Last Updated
3 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Patri-cia Angelica de Miranda Silva Nogueira

Professora associada da UFRN

Universidade Federal do Rio Grande do Norte

Eligibility Criteria

Inclusion Criteria

  • Clinically stable COPD patients (diagnosed according to the Global Initiative for Obstructive Lung Disease), of both sexes, without exacerbation or changes in medication for at least one month before the study, and no dyspnea during daily activities (grades 2, 3, and 4 of the Medical Research Council - MRC scale) were included.

Exclusion Criteria

  • Those with a diagnosis of neoplasia, orthopedic or neurological conditions affecting exercise capacity, peripheral arterial obstructive disease, heart failure, kidney or liver disease, did not adapt, or failed to complete the study procedures, were excluded.

Outcomes

Primary Outcomes

Lung function

Time Frame: change from baseline and 30 minutes after intervention

Lung function was assessed using a spirometer (Koko Digidoser, Longmont, USA), according to the American Thoracic Society/European Throracic Society recommendations14. At least three tests were performed, with a variation of less than 5%, and the highest value obtained was compared with predicted values for the Brazilian population.

Functional capacity

Time Frame: change from baseline and 30 minutes after intervention

The 6-minute walk test (6MWT) was performed in a flat 30-m corridor, according to the ATS recommendations17. Subjects were instructed to keep walking for six minutes, and standardized verbal incentives were given each minute. The perception of dyspnea (using the 10-point Borg scale) were assessed at rest, at the end of the 6MWT, and two minutes after the test. In this test, the walked distance (in meters) was considered for analysis.

Disease severity

Time Frame: change from baseline and 30 minutes after intervention

COPD severity was assessed using the BODE index (body mass index \[B\], degree of airway obstruction \[O\], dyspnea \[D\], and exercise capacity \[E\]). For each variable, the following scores were assigned: body mass index (BMI), from 0 to 1 point; degree of airflow obstruction (FEV1% predicted), from 0 to 3 points; dyspnea (MRC scale), from 0 to 3 points; exercise capacity (walked distance in the 6MWT), from 0 to 3 points. The final score of the index ranges from 0 to 10, with higher scores indicating greater disease severity.

Respiratory muscle strength

Time Frame: change from baseline and 30 minutes after intervention

Respiratory muscle strength was assessed using a digital manometer (MVD 300 - Brazil). Maximum inspiratory and expiratory pressures were performed from residual volume and total lung capacity, respectively, and values were compared with previously reference values for the Brazilian population

COPD Assessement Test

Time Frame: change from baseline and 30 minutes after intervention

The Portuguese version of the COPD Assessment Test (CAT) questionnaire was used to assess the quality of life. Subjects were instructed to choose only one option in each item of the questionnaire (cough, phlegm, chest tightness, breathlessness, limited activities, confidence leaving home, sleeplessness, and energy). Item scores range from 0 to 5 points resulting in a total score ranging from 0 to 40 points. The clinical impact of COPD was assessed according to the following stratification: mild (6-10), moderate (11-20), severe (21-30), and very severe (31-40)20.

Secondary Outcomes

  • Quadriceps femoris performance(change from baseline and 30 minutes after intervention)
  • Biochemical analyzes(change from baseline and 30 minutes intervention)

Study Sites (1)

Loading locations...

Similar Trials